Treatment of Diabetic Neuropathy With Liraglutide

NCT02138045 · Completed

Last updated 2026-05-28

This clinical trial is testing whether liraglutide, a medication, can help reduce nerve pain in adults with type 1 diabetes.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 39 people

Who can join Ages 18+ · all sexes

Timeline Started 2014-05 · est. completion 2017-02

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02138045 ↗

Description as written by the study sponsor.

The purpose of this trial is to explore whether liraglutide has a long term effect on clinical symptoms and biomarkers in patients with diabetic neuropathy.

Treatments tested

Placebo treatment Drug

Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
Liraglutide treatment Drug

Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.

Main thing measured	RIII withdrawal reflex activity (using standard electromyography)
Sponsor	Aalborg University Hospital
Conditions studied	Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02138045 ↗